Quick Summary
Researchers tested whether a drug called CCSA (a compound containing succinate acid) could help people with post-COVID fatigue and brain fog. They used advanced brain imaging scans to measure changes in brain activity before and after treatment. The CCSA group showed greater improvement in fatigue symptoms and thinking skills compared to the placebo group.
Why It Matters
Post-COVID fatigue shares phenotypic overlap with ME/CFS, and this study provides objective neuroimaging evidence linking symptom improvement to measurable changes in brain function. Understanding neuroprotective mechanisms in post-COVID populations may inform therapeutic approaches applicable to ME/CFS, where cognitive dysfunction and fatigue are core features.
Observed Findings
What the study reports it measured.
- CCSA-treated patients showed greater reduction in fatigue severity on MFI-20 scale (−20 points vs −12 points in placebo, p=0.043)
- Cognitive scores on MoCA improved more in CCSA group (+2 points vs +1 point, p<0.05)
- Task-based fMRI and resting-state fMRI showed changes in brain activation patterns correlating with clinical improvement in CCSA group
- No adverse events or safety concerns reported for CCSA treatment
- Both groups completed pre- and post-treatment assessment with matched demographic characteristics
Inferred Conclusions
What the authors interpret from those results.
- CCSA demonstrates potential neuroprotective efficacy across multiple symptom domains (fatigue and cognitive impairment) in post-COVID syndrome
- Functional neuroimaging changes correlate with clinical symptom improvement following CCSA therapy
- High-field fMRI can serve as an objective biomarker for treatment response monitoring in post-COVID asthenic syndrome
Remaining Questions
- What is the optimal dose and duration of CCSA treatment, and does efficacy persist beyond the treatment period?
- Does CCSA effectiveness extend to primary ME/CFS or other post-viral fatigue syndromes, or is it specific to post-COVID presentations?
- What are the mechanistic pathways by which CCSA exerts neuroprotection—does it improve mitochondrial function, reduce neuroinflammation, or restore specific neural networks?
- What is the long-term safety and tolerability profile of CCSA with extended treatment duration?
What This Study Does Not Prove
This study does not prove CCSA is effective for ME/CFS or primary post-viral fatigue broadly—findings are specific to post-COVID asthenic syndrome in this sample. Small sample size (n=15 per group) limits generalizability. The study demonstrates correlation between neuroimaging changes and clinical improvement but does not establish whether brain imaging changes are mechanistically responsible for symptom relief or merely associated with it.
Explore further
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Cite this study
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Tanashyan, M, Morozova, S, Raskurazhev, A, & Kuznetsova, P (2023). A prospective randomized, double-blind placebo-controlled study to evaluate the effectiveness of neuroprotective therapy using functional brain MRI in patients with post-covid chronic fatigue syndrome.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. https://doi.org/10.1016/j.biopha.2023.115723
BibTeX
@article{mecfsatlas-tanashyan-2023-prospective-randomized,
author = {Tanashyan, M and Morozova, S and Raskurazhev, A and Kuznetsova, P},
title = {A prospective randomized, double-blind placebo-controlled study to evaluate the effectiveness of neuroprotective therapy using functional brain MRI in patients with post-covid chronic fatigue syndrome.},
journal = {Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie},
year = {2023},
doi = {10.1016/j.biopha.2023.115723},
note = {PubMed: 37862966},
url = {https://www.mecfsatlas.com/evidence/tanashyan-2023-prospective-randomized},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-14. https://www.mecfsatlas.com/evidence/tanashyan-2023-prospective-randomized
Contribute
Private, reviewed by a human. Not a public comment thread.